Amunix Operating has entered into a licensing agreement with Celgene.    The agreement allows for the utilization of Amunix’s proprietary XTEN and ProTIA technology to augment ongoing discovery and development of therapeutics with the potential for improved delivery, enhanced safety, targeted delivery, and half-life attributes against specified targets selected by Celgene.   ProTIAs are bispecific molecules that bind tumor antigens and T cells. They are administered as long-actin...